Search Results for "International%20drug%20pricing"

Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.

Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.

Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.

Our response to the Trump administration’s Request for Information on implementing an international pricing index model for Medicare Part B drugs.

To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.